| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head Injuries, Penetrating | 10 | 2025 | 67 | 3.070 |
Why?
|
| Brain Injuries | 8 | 2023 | 139 | 1.910 |
Why?
|
| Cerebral Hemorrhage | 12 | 2025 | 362 | 1.570 |
Why?
|
| Inpatients | 4 | 2021 | 341 | 1.490 |
Why?
|
| Emergency Service, Hospital | 4 | 2021 | 576 | 1.480 |
Why?
|
| Stroke | 8 | 2024 | 1073 | 1.370 |
Why?
|
| Brain Death | 5 | 2023 | 87 | 1.130 |
Why?
|
| Brain Injuries, Traumatic | 5 | 2023 | 124 | 1.120 |
Why?
|
| Brain Ischemia | 4 | 2020 | 407 | 1.090 |
Why?
|
| Intracranial Pressure | 4 | 2023 | 75 | 0.900 |
Why?
|
| Wounds, Gunshot | 3 | 2025 | 121 | 0.880 |
Why?
|
| Family | 2 | 2023 | 319 | 0.860 |
Why?
|
| Intracranial Hypertension | 3 | 2023 | 55 | 0.800 |
Why?
|
| Thrombolytic Therapy | 4 | 2021 | 253 | 0.790 |
Why?
|
| Intracranial Hemorrhages | 3 | 2020 | 135 | 0.770 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2020 | 4 | 0.670 |
Why?
|
| Hypopituitarism | 1 | 2020 | 17 | 0.660 |
Why?
|
| Adrenal Insufficiency | 1 | 2020 | 23 | 0.660 |
Why?
|
| Vascular System Injuries | 1 | 2021 | 37 | 0.660 |
Why?
|
| Intracranial Thrombosis | 1 | 2020 | 31 | 0.610 |
Why?
|
| Neurologic Examination | 1 | 2020 | 118 | 0.610 |
Why?
|
| Thrombectomy | 2 | 2024 | 220 | 0.580 |
Why?
|
| Hematoma | 4 | 2025 | 105 | 0.560 |
Why?
|
| Ischemic Attack, Transient | 1 | 2020 | 184 | 0.560 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 185 | 0.550 |
Why?
|
| Hypothyroidism | 1 | 2020 | 275 | 0.540 |
Why?
|
| Retrospective Studies | 20 | 2025 | 10128 | 0.520 |
Why?
|
| Humans | 61 | 2025 | 93132 | 0.430 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 334 | 0.430 |
Why?
|
| Hypoxia-Ischemia, Brain | 2 | 2022 | 54 | 0.340 |
Why?
|
| Injury Severity Score | 2 | 2021 | 152 | 0.310 |
Why?
|
| Middle Aged | 28 | 2025 | 27535 | 0.300 |
Why?
|
| Cryotherapy | 1 | 2009 | 30 | 0.290 |
Why?
|
| Body Temperature Regulation | 1 | 2009 | 59 | 0.290 |
Why?
|
| Prognosis | 7 | 2021 | 3890 | 0.270 |
Why?
|
| Neurosurgical Procedures | 5 | 2023 | 350 | 0.270 |
Why?
|
| Aged | 19 | 2025 | 20395 | 0.270 |
Why?
|
| Fever | 1 | 2009 | 121 | 0.270 |
Why?
|
| Brain Stem | 4 | 2020 | 163 | 0.260 |
Why?
|
| Brain Edema | 3 | 2020 | 54 | 0.260 |
Why?
|
| Male | 28 | 2025 | 44355 | 0.240 |
Why?
|
| Decompressive Craniectomy | 2 | 2025 | 21 | 0.240 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 168 | 0.240 |
Why?
|
| Female | 32 | 2025 | 48542 | 0.240 |
Why?
|
| Subarachnoid Hemorrhage | 5 | 2008 | 152 | 0.240 |
Why?
|
| Time Factors | 5 | 2021 | 5380 | 0.230 |
Why?
|
| Platelet Activation | 1 | 2025 | 17 | 0.230 |
Why?
|
| Treatment Outcome | 12 | 2024 | 9070 | 0.230 |
Why?
|
| Neurology | 2 | 2017 | 83 | 0.230 |
Why?
|
| Thrombelastography | 1 | 2025 | 47 | 0.220 |
Why?
|
| Blood Platelets | 1 | 2025 | 149 | 0.220 |
Why?
|
| Heart Arrest | 2 | 2022 | 310 | 0.210 |
Why?
|
| Intensive Care Units | 3 | 2023 | 450 | 0.210 |
Why?
|
| Coma | 2 | 2021 | 44 | 0.200 |
Why?
|
| Neuroimaging | 1 | 2025 | 132 | 0.200 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 451 | 0.200 |
Why?
|
| Critical Care | 3 | 2017 | 442 | 0.200 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2025 | 177 | 0.200 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1703 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2025 | 2562 | 0.190 |
Why?
|
| Seizures | 2 | 2020 | 312 | 0.180 |
Why?
|
| Models, Biological | 1 | 2009 | 1768 | 0.180 |
Why?
|
| Intracranial Aneurysm | 3 | 2020 | 201 | 0.170 |
Why?
|
| Embolization, Therapeutic | 1 | 2024 | 272 | 0.170 |
Why?
|
| Length of Stay | 2 | 2023 | 820 | 0.170 |
Why?
|
| Hospitalization | 3 | 2021 | 924 | 0.170 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2021 | 12 | 0.170 |
Why?
|
| Head Injuries, Closed | 1 | 2020 | 11 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2022 | 4546 | 0.160 |
Why?
|
| Pituitary-Adrenal System | 1 | 2020 | 64 | 0.160 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2020 | 18 | 0.160 |
Why?
|
| Hypocalcemia | 1 | 2020 | 43 | 0.160 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 78 | 0.160 |
Why?
|
| Apnea | 1 | 2020 | 32 | 0.160 |
Why?
|
| Hemostatics | 1 | 2021 | 60 | 0.160 |
Why?
|
| Prevalence | 3 | 2021 | 1318 | 0.160 |
Why?
|
| Heuristics | 1 | 2020 | 15 | 0.160 |
Why?
|
| Neurosurgery | 2 | 2021 | 140 | 0.160 |
Why?
|
| Amantadine | 1 | 2020 | 17 | 0.160 |
Why?
|
| Triage | 1 | 2021 | 131 | 0.160 |
Why?
|
| Nootropic Agents | 1 | 2020 | 12 | 0.160 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 103 | 0.160 |
Why?
|
| Heart Conduction System | 1 | 2021 | 135 | 0.160 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 66 | 0.160 |
Why?
|
| Cognition Disorders | 2 | 2020 | 235 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 1054 | 0.150 |
Why?
|
| Mortality | 1 | 2020 | 156 | 0.150 |
Why?
|
| Heart Rate | 3 | 2021 | 505 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 496 | 0.150 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 17 | 0.150 |
Why?
|
| Survivors | 1 | 2020 | 204 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 222 | 0.150 |
Why?
|
| Thyroid Gland | 1 | 2020 | 280 | 0.150 |
Why?
|
| Respiratory Therapy | 1 | 2019 | 16 | 0.150 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2020 | 180 | 0.150 |
Why?
|
| Caregivers | 1 | 2021 | 171 | 0.150 |
Why?
|
| Incidence | 3 | 2020 | 1697 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 618 | 0.140 |
Why?
|
| Acute Disease | 1 | 2020 | 838 | 0.140 |
Why?
|
| Electroencephalography | 1 | 2023 | 798 | 0.140 |
Why?
|
| Drug Therapy | 1 | 2019 | 67 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 238 | 0.140 |
Why?
|
| Hospitals, University | 1 | 2019 | 188 | 0.140 |
Why?
|
| Electrocardiography | 1 | 2021 | 496 | 0.140 |
Why?
|
| Thrombocytosis | 1 | 2018 | 7 | 0.140 |
Why?
|
| Plateletpheresis | 1 | 2018 | 2 | 0.140 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2018 | 5 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 2479 | 0.140 |
Why?
|
| Chicago | 2 | 2020 | 1452 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2022 | 403 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2020 | 218 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 290 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2020 | 753 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 389 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 168 | 0.130 |
Why?
|
| Action Potentials | 1 | 2021 | 578 | 0.130 |
Why?
|
| Adult | 19 | 2025 | 27849 | 0.130 |
Why?
|
| Brain | 5 | 2025 | 2337 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1849 | 0.120 |
Why?
|
| Disease Management | 1 | 2018 | 357 | 0.110 |
Why?
|
| Societies, Medical | 2 | 2017 | 618 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 338 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 333 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 257 | 0.100 |
Why?
|
| Macroglossia | 1 | 2014 | 7 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2705 | 0.100 |
Why?
|
| Pregnatrienes | 3 | 2007 | 14 | 0.100 |
Why?
|
| Glasgow Coma Scale | 2 | 2023 | 72 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2021 | 2434 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 38 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage, Traumatic | 1 | 2012 | 3 | 0.090 |
Why?
|
| Neuromuscular Diseases | 1 | 2012 | 25 | 0.090 |
Why?
|
| Ammonia | 1 | 2011 | 34 | 0.090 |
Why?
|
| Hyperammonemia | 1 | 2011 | 14 | 0.090 |
Why?
|
| Hepatic Encephalopathy | 1 | 2011 | 35 | 0.090 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 7039 | 0.090 |
Why?
|
| Risk Factors | 6 | 2022 | 5900 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2025 | 3044 | 0.090 |
Why?
|
| Hospitals | 1 | 2013 | 329 | 0.080 |
Why?
|
| Hypothermia, Induced | 1 | 2011 | 88 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 278 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2025 | 480 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2013 | 541 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2012 | 280 | 0.080 |
Why?
|
| Qualitative Research | 2 | 2021 | 346 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 199 | 0.070 |
Why?
|
| Blood Physiological Phenomena | 1 | 2009 | 9 | 0.070 |
Why?
|
| Ice | 1 | 2009 | 11 | 0.070 |
Why?
|
| Adolescent | 6 | 2025 | 9550 | 0.070 |
Why?
|
| Quadriplegia | 1 | 2008 | 30 | 0.070 |
Why?
|
| Hernia | 1 | 2008 | 21 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 916 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2009 | 83 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2011 | 246 | 0.070 |
Why?
|
| Cold Temperature | 1 | 2009 | 159 | 0.070 |
Why?
|
| Machine Learning | 2 | 2022 | 346 | 0.070 |
Why?
|
| Eye Movements | 1 | 2008 | 119 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 400 | 0.070 |
Why?
|
| Encephalitis | 1 | 2008 | 46 | 0.070 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2007 | 5 | 0.070 |
Why?
|
| Tremor | 1 | 2007 | 22 | 0.060 |
Why?
|
| Aneurysm, Ruptured | 1 | 2007 | 60 | 0.060 |
Why?
|
| Fingers | 1 | 2007 | 51 | 0.060 |
Why?
|
| Young Adult | 3 | 2025 | 6922 | 0.060 |
Why?
|
| Biomarkers | 2 | 2025 | 1905 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2007 | 127 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 810 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 1000 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 873 | 0.060 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2005 | 3 | 0.060 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 2005 | 4 | 0.060 |
Why?
|
| Torticollis | 1 | 2005 | 12 | 0.060 |
Why?
|
| Dystonic Disorders | 1 | 2005 | 8 | 0.050 |
Why?
|
| Botulinum Toxins | 1 | 2005 | 16 | 0.050 |
Why?
|
| Patient Admission | 2 | 2021 | 118 | 0.050 |
Why?
|
| Craniotomy | 1 | 2005 | 88 | 0.050 |
Why?
|
| Vasospasm, Intracranial | 1 | 2004 | 36 | 0.050 |
Why?
|
| Minority Groups | 1 | 2005 | 149 | 0.050 |
Why?
|
| Radial Artery | 1 | 2024 | 37 | 0.050 |
Why?
|
| Neurophysiological Monitoring | 1 | 2023 | 17 | 0.050 |
Why?
|
| Decompression, Surgical | 1 | 2005 | 157 | 0.050 |
Why?
|
| Global Health | 1 | 2025 | 207 | 0.050 |
Why?
|
| Catheters | 1 | 2024 | 96 | 0.050 |
Why?
|
| Latin America | 1 | 2023 | 17 | 0.050 |
Why?
|
| Disease Progression | 2 | 2021 | 1529 | 0.050 |
Why?
|
| Income | 1 | 2023 | 86 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2023 | 57 | 0.050 |
Why?
|
| Death | 1 | 2023 | 95 | 0.050 |
Why?
|
| Swine | 1 | 2023 | 585 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2023 | 229 | 0.040 |
Why?
|
| Cranial Fossa, Posterior | 2 | 2014 | 23 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2023 | 255 | 0.040 |
Why?
|
| Resuscitation | 1 | 2022 | 129 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 1519 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 165 | 0.040 |
Why?
|
| Electrolytes | 1 | 2020 | 52 | 0.040 |
Why?
|
| Double-Blind Method | 4 | 2007 | 1727 | 0.040 |
Why?
|
| Life Support Care | 1 | 2021 | 54 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2021 | 121 | 0.040 |
Why?
|
| Spinal Injuries | 1 | 2020 | 28 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2013 | 292 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2020 | 77 | 0.040 |
Why?
|
| Patient Participation | 1 | 2021 | 229 | 0.040 |
Why?
|
| Craniocerebral Trauma | 1 | 2020 | 52 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 328 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 83 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2020 | 117 | 0.040 |
Why?
|
| Snoring | 2 | 1996 | 12 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 234 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 458 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 282 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2020 | 340 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 455 | 0.030 |
Why?
|
| Glasgow Outcome Scale | 2 | 2007 | 9 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1102 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 393 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2014 | 108 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 1004 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 561 | 0.030 |
Why?
|
| Decision Making | 1 | 2021 | 671 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1188 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2020 | 432 | 0.030 |
Why?
|
| Neuroprotective Agents | 2 | 2007 | 94 | 0.030 |
Why?
|
| Catalepsy | 1 | 1994 | 3 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 1996 | 124 | 0.030 |
Why?
|
| Benzhydryl Compounds | 1 | 1994 | 46 | 0.030 |
Why?
|
| Primary Dysautonomias | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2014 | 17 | 0.030 |
Why?
|
| Amines | 1 | 2014 | 31 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2014 | 118 | 0.020 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2014 | 84 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2014 | 45 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 18 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2008 | 3450 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2014 | 311 | 0.020 |
Why?
|
| Central Nervous System Stimulants | 1 | 1994 | 233 | 0.020 |
Why?
|
| Abdomen | 1 | 1992 | 118 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2012 | 100 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 120 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2012 | 134 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2011 | 75 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 353 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 1991 | 53 | 0.020 |
Why?
|
| Child | 1 | 2022 | 7273 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 254 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 750 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2011 | 515 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 1 | 1991 | 137 | 0.020 |
Why?
|
| Hypertension | 1 | 1996 | 748 | 0.020 |
Why?
|
| United States | 1 | 2023 | 7581 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 27973 | 0.020 |
Why?
|
| Pons | 1 | 2008 | 25 | 0.020 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2008 | 9 | 0.020 |
Why?
|
| Sleep | 1 | 1992 | 448 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 2008 | 78 | 0.020 |
Why?
|
| Prednisone | 1 | 2008 | 242 | 0.020 |
Why?
|
| Oxygen | 1 | 1992 | 749 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 432 | 0.020 |
Why?
|
| Toes | 1 | 2007 | 15 | 0.020 |
Why?
|
| Hypoxia | 1 | 1992 | 672 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2007 | 204 | 0.020 |
Why?
|
| Mandibular Diseases | 1 | 2005 | 17 | 0.010 |
Why?
|
| Mouth Diseases | 1 | 2005 | 14 | 0.010 |
Why?
|
| Wakefulness | 2 | 1996 | 128 | 0.010 |
Why?
|
| Posture | 1 | 2005 | 121 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3431 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 2004 | 213 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1992 | 2552 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 3814 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 12230 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 3781 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1996 | 46 | 0.010 |
Why?
|
| Sex Ratio | 1 | 1996 | 22 | 0.010 |
Why?
|
| Sleep Stages | 1 | 1996 | 45 | 0.010 |
Why?
|
| Polysomnography | 1 | 1996 | 152 | 0.010 |
Why?
|
| Arousal | 1 | 1996 | 171 | 0.010 |
Why?
|
| Fatigue | 1 | 1996 | 181 | 0.010 |
Why?
|
| Placebos | 1 | 1994 | 205 | 0.010 |
Why?
|
| Respiration | 1 | 1996 | 268 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 1996 | 256 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1994 | 389 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1996 | 806 | 0.010 |
Why?
|
| Oximetry | 1 | 1992 | 88 | 0.010 |
Why?
|
| France | 1 | 1991 | 52 | 0.010 |
Why?
|
| Age Factors | 1 | 1996 | 1898 | 0.010 |
Why?
|
| Drug Utilization | 1 | 1991 | 63 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1994 | 887 | 0.010 |
Why?
|
| Anxiety | 1 | 1991 | 336 | 0.000 |
Why?
|
| Depression | 1 | 1991 | 540 | 0.000 |
Why?
|